% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • madmoneyguru madmoneyguru Apr 15, 2013 6:35 PM Flag

    FDA asking for dystrophin because GSK's drug DOESN'T DO IT.

    The FDA is asking for dystrophin as a surrogate endpoing, because the GSK drug doesn't do it and this will directly support AA and rapid approval of eteplirsen. Faster than anybody expects. Watch it happen in 2013.

12.22-0.01(-0.08%)Feb 5 4:00 PMEST